PERICARDIAL REPAIR TODAY IMPROVING REOPERATION TOMORROW Flyer - Congenital Heart Defect - Pericardial Repair See more
03/2021 GORE REDUCE CLINICAL STUDY FIVE-YEAR RESULTS DEMONSTRATE THAT PFO CLOSURE WITH THE GORE® CARDIOFORM SEPTAL OCCLUDER PROVIDES SAFE LONG-TERM REDUCTION OF RECURRENT STROKE FLAGSTAFF, Ariz. (March 11, 2021)— W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention. See more
Reline using GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* as first line therapy when treating complex in-stent restenosis (ISR) In a TASC II Type C lesion, “kissing” placement of the VBX Stent Graft successfully reconstructs the aortic bifurcation. See more